209 related articles for article (PubMed ID: 19770360)
1. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease.
Brewin J; Mancao C; Straathof K; Karlsson H; Samarasinghe S; Amrolia PJ; Pule M
Blood; 2009 Nov; 114(23):4792-803. PubMed ID: 19770360
[TBL] [Abstract][Full Text] [Related]
2. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506).
De Angelis B; Dotti G; Quintarelli C; Huye LE; Zhang L; Zhang M; Pane F; Heslop HE; Brenner MK; Rooney CM; Savoldo B
Blood; 2009 Nov; 114(23):4784-91. PubMed ID: 19759356
[TBL] [Abstract][Full Text] [Related]
3. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.
Ricciardelli I; Blundell MP; Brewin J; Thrasher A; Pule M; Amrolia PJ
Blood; 2014 Oct; 124(16):2514-22. PubMed ID: 25185261
[TBL] [Abstract][Full Text] [Related]
4. Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy.
Ricciardelli I; Brewin J; Lugthart G; Albon SJ; Pule M; Amrolia PJ
Am J Transplant; 2013 Dec; 13(12):3244-52. PubMed ID: 24266973
[TBL] [Abstract][Full Text] [Related]
5. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.
Savoldo B; Goss J; Liu Z; Huls MH; Doster S; Gee AP; Brenner MK; Heslop HE; Rooney CM
Transplantation; 2001 Sep; 72(6):1078-86. PubMed ID: 11579304
[TBL] [Abstract][Full Text] [Related]
6. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.
Comoli P; Labirio M; Basso S; Baldanti F; Grossi P; Furione M; Viganò M; Fiocchi R; Rossi G; Ginevri F; Gridelli B; Moretta A; Montagna D; Locatelli F; Gerna G; Maccario R
Blood; 2002 Apr; 99(7):2592-8. PubMed ID: 11895798
[TBL] [Abstract][Full Text] [Related]
7. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
Burns DM; Crawford DH
Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
[TBL] [Abstract][Full Text] [Related]
9. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
[TBL] [Abstract][Full Text] [Related]
10. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
Davis JE; Moss DJ
Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
[TBL] [Abstract][Full Text] [Related]
11. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
Vickers MA; Wilkie GM; Robinson N; Rivera N; Haque T; Crawford DH; Barry J; Fraser N; Turner DM; Robertson V; Dyer P; Flanagan P; Newlands HR; Campbell J; Turner ML
Br J Haematol; 2014 Nov; 167(3):402-10. PubMed ID: 25066775
[TBL] [Abstract][Full Text] [Related]
12. Calcineurin mutants render T lymphocytes resistant to cyclosporin A.
Zhu D; Cardenas ME; Heitman J
Mol Pharmacol; 1996 Sep; 50(3):506-11. PubMed ID: 8794888
[TBL] [Abstract][Full Text] [Related]
13. Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation.
Hoffmann T; Russell C; Vindelov L
APMIS; 2002 Feb; 110(2):148-57. PubMed ID: 12064870
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.
Thieme CJ; Schulz M; Wehler P; Anft M; Amini L; Blàzquez-Navarro A; Stervbo U; Hecht J; Nienen M; Stittrich AB; Choi M; Zgoura P; Viebahn R; Schmueck-Henneresse M; Reinke P; Westhoff TH; Roch T; Babel N
Kidney Int; 2022 Dec; 102(6):1392-1408. PubMed ID: 36103953
[TBL] [Abstract][Full Text] [Related]
15. EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review.
Liu JY; Zhang JM; Zhan HS; Sun LY; Wei L
Transpl Int; 2021 Dec; 34(12):2483-2493. PubMed ID: 34510581
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.
Haque T; Wilkie GM; Jones MM; Higgins CD; Urquhart G; Wingate P; Burns D; McAulay K; Turner M; Bellamy C; Amlot PL; Kelly D; MacGilchrist A; Gandhi MK; Swerdlow AJ; Crawford DH
Blood; 2007 Aug; 110(4):1123-31. PubMed ID: 17468341
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporin a inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells.
Eckstein LA; Van Quill KR; Bui SK; Uusitalo MS; O'Brien JM
Invest Ophthalmol Vis Sci; 2005 Mar; 46(3):782-90. PubMed ID: 15728531
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
[TBL] [Abstract][Full Text] [Related]
19. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease.
Bollard CM; Savoldo B; Rooney CM; Heslop HE
Acta Haematol; 2003; 110(2-3):139-48. PubMed ID: 14583674
[TBL] [Abstract][Full Text] [Related]
20. Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.
Swinnen LJ
Best Pract Res Clin Haematol; 2006; 19(4):839-47. PubMed ID: 16997187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
